Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Financing Activities (2016 - 2025)

Regenxbio (RGNX) has 12 years of Cash from Financing Activities data on record, last reported at -$9.6 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 23.82% year-over-year to -$9.6 million; the TTM value through Dec 2025 reached $116.8 million, up 25.99%, while the annual FY2025 figure was $116.8 million, 25.99% up from the prior year.
  • Cash from Financing Activities reached -$9.6 million in Q4 2025 per RGNX's latest filing, down from -$7.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $211.3 million in Q1 2021 and bottomed at -$12.0 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $17.0 million, with a median of -$7.3 million recorded in 2021.
  • The widest YoY moves for Cash from Financing Activities: up 7552.52% in 2021, down 436.27% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at -$7.6 million in 2021, then decreased by 17.12% to -$8.9 million in 2022, then plummeted by 34.1% to -$12.0 million in 2023, then surged by 35.3% to -$7.7 million in 2024, then dropped by 23.82% to -$9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$9.6 million in Q4 2025, -$7.1 million in Q3 2025, and $139.2 million in Q2 2025.